CytRx has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate – arimoclomol.
Arimoclomol is said to represent a novel approach to the treatment of central nervous system (CNS) disorders by activating molecular chaperones that regulate the normal cellular protein repair pathway.
Reportedly, the granted patent (EP1696922) broadens CytRx’s existing coverage in the EU for arimoclomol that includes composition of matter claims.
Steven Kriegsman, president and CEO of CytRx, said: “This expanded patent protection is noteworthy as we believe arimoclomol has significant potential in multiple progressive, chronic CNS disorders, such as amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), Huntington’s disease, Parkinson’s Disease and Alzheimer’s disease, which are increasing in prevalence with longer life expectancy. We are pursuing similar coverage in the US with an active patent application pending.
“Broadened European patent coverage supports our activities to attract a biotechnology or pharmaceutical partner for the development of arimoclomol for all indications on a worldwide basis.”